Assessing Alzheimer disease risk and heterogeneity using multimodal machine learning approaches

Information

  • Research Project
  • 10296695
  • ApplicationId
    10296695
  • Core Project Number
    U01AG068221
  • Full Project Number
    1U01AG068221-01A1
  • Serial Number
    068221
  • FOA Number
    PAR-19-269
  • Sub Project Id
  • Project Start Date
    9/15/2021 - 2 years ago
  • Project End Date
    8/31/2025 - a year from now
  • Program Officer Name
    LARKIN, JENNIE
  • Budget Start Date
    9/15/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    9/10/2021 - 2 years ago
Organizations

Assessing Alzheimer disease risk and heterogeneity using multimodal machine learning approaches

PROJECT SUMMARY/ABSTRACT Alzheimer's disease (AD) is the most common form of dementia characterized by progressive loss of cognitive function. Unfortunately, currently there is no effective treatment for AD and clinical interventions of AD have largely failed despite enormous efforts. For the current application, we seek to develop multimodal machine learning models by leveraging the rich collection of AD-related omics data and phenotypical data recently generated from large-scale collaborative projects such as Alzheimer Disease Neuroimaging Initiative (ADNI), Accelerating Medicines Partnership-AD (AMP-AD) and the Alzheimer's Disease Sequencing Project (ADSP). Three aims will be pursued in the current application. Aim 1. We will build an expandable multimodal unsupervised machine learning framework to investigate AD heterogeneity. Given the multifactorial nature of AD, we will perform AD subtyping by harnessing the rich information across multiple spectrum of data. Aim 2. We will build an expandable multimodal supervised machine learning framework to quantify AD risk from longitudinal follow up of cognitively normal elders. The models will be built from genetic susceptibility and gene regulatory information as well as endophenotypes measured when participants were cognitive normal. Aim 3. We will build AD-related gene interaction networks in post-mortem human brain samples. We will examine the association of multiple omics data with AD in brain samples, and build tissue-specific interaction networks to understand potential molecular mechanisms underlying AD pathogenesis. The present application represents an innovative approach to identify individuals at high risk of AD from both clinical and genetic risk factors in ethnically diverse populations. The outlined strategy will provide new insights into the risk stratification and prevention strategies for AD. We also commit to share our methods through GitHub or CRAN for free access across the scientific community.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    U01
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
    403258
  • Indirect Cost Amount
    213667
  • Total Cost
    616925
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIA:616925\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    NIA
  • Study Section Name
    Neuroscience of Aging Review Committee
  • Organization Name
    BOSTON UNIVERSITY MEDICAL CAMPUS
  • Organization Department
    INTERNAL MEDICINE/MEDICINE
  • Organization DUNS
    604483045
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021182841
  • Organization District
    UNITED STATES